Exploration on the construction of a bladder cancer prognostic model based on disulfidptosis-related lncRNAs and its clinical significance

被引:0
|
作者
Hu, Xian-Cun [1 ]
Yu, Qi-Ying [2 ]
Ding, Hai-Ping [1 ]
Xiao, Feng [3 ]
Gu, Chun-Yan [3 ]
机构
[1] Nantong Univ, Med Sch, Nantong 226007, Jiangsu, Peoples R China
[2] Nantong Univ, Nantong Tumor Hosp, Affiliated Tumor Hosp, Canc Res Ctr, Nantong 226361, Jiangsu, Peoples R China
[3] Nantong Univ, Nantong Peoples Hosp 3, Affiliated Nantong Hosp 3, Dept Pathol, Nantong 226006, Jiangsu, Peoples R China
来源
SCIENTIFIC REPORTS | 2024年 / 14卷 / 01期
关键词
Bladder cancer; Disulfidptosis; lncRNA; TCGA database; Prognosis;
D O I
10.1038/s41598-024-78481-5
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Disulfidptosis is a novel programmed cell death mode that has been reported to play a role in oncogenesis. Increasing evidences suggest that the long non-coding RNAs (lncRNAs) play crucial roles in the initiation and progression of bladder cancer (BLCA). However, the role and prognostic value of disulfidptosis-related lncRNAs in BLCA remain unknown.The aim of this study was to construct and validate a disulfidptosis-related lncRNA risk model for predicting the prognosis of BLCA patients. A risk model consisting of 5 disulfidptosis-related lncRNAs was developed to predict the prognosis of BLCA patients. The overall survival (OS) of BLCA patients in the high-risk group was significantly shorter than that in the low-risk group (P < 0.05). The effectiveness of this model was validated using the receiver operating characteristic (ROC) curve analysis, and this model proved superior in prognostic accuracy compared with other clinical features. Furthermore, the tumor immune dysfunction and exclusion (TIDE) score in the high-risk group was significantly higher than that in the low-risk group, suggesting that the high-risk group had a less favorable response to immunotherapy. Simultaneously, patients in the low-risk group exhibited significantly higher sensitivity to CTLA-4 monoclonal antibody therapy compared to those in the high-risk group, suggesting potential benefits of immunotherapy for patients in the low-risk group. The combination of high risk and low tumor mutational burden (TMB) could further shortened the OS of BLCA patients. Lastly, the drug sensitivity analysis revealed that the BLCA cells in the high-risk group showed an increased sensitivity to cisplatin, sunitinib, cetuximab, axitinib, docetaxel, saracatinib, vinblastine and pazopanib compared with those in the low-risk group. According to the Quantitative real time PCR results, we found that five lncRNAs of the risk model were more highly expressed in BCa cell lines than human immortalized uroepithelial cell line. The disulfidptosis-related lncRNA risk model has a valuable effect in assessing the prognosis of BLCA patients.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Development and validation of a disulfidptosis-related prognostic model for colorectal cancer using multi-omics analysis
    Shi, Lei
    Wang, Huimei
    Sun, Yongxiao
    Xu, Na
    Pei, Aiyue
    Zhang, Nan
    DISCOVER ONCOLOGY, 2025, 16 (01)
  • [42] Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework
    Zhao, Songyun
    Wang, Lanyu
    Ding, Wei
    Ye, Bicheng
    Cheng, Chao
    Shao, Jianfeng
    Liu, Jinhui
    Zhou, Hongyi
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [43] Integrating bioinformatics and experimental validation to unveil disulfidptosis-related lncRNAs as prognostic biomarker and therapeutic target in hepatocellular carcinoma
    Lixia Xu
    Shu Chen
    Qiaoqiao Li
    Xinyi Chen
    Yuan Xu
    Yongjian Zhou
    Juan Li
    Zhixian Guo
    Jiyuan Xing
    Di Chen
    Cancer Cell International, 24
  • [44] Unraveling the role of disulfidptosis-related LncRNAs in colon cancer: a prognostic indicator for immunotherapy response, chemotherapy sensitivity, and insights into cell death mechanisms
    Chi, Hao
    Huang, Jinbang
    Yan, Yang
    Jiang, Chenglu
    Zhang, Shengke
    Chen, Haiqing
    Jiang, Lai
    Zhang, Jieying
    Zhang, Qinghong
    Yang, Guanhu
    Tian, Gang
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2023, 10
  • [45] Integrating bioinformatics and experimental validation to unveil disulfidptosis-related lncRNAs as prognostic biomarker and therapeutic target in hepatocellular carcinoma
    Xu, Lixia
    Chen, Shu
    Li, Qiaoqiao
    Chen, Xinyi
    Xu, Yuan
    Zhou, Yongjian
    Li, Juan
    Guo, Zhixian
    Xing, Jiyuan
    Chen, Di
    CANCER CELL INTERNATIONAL, 2024, 24 (01)
  • [46] Prognostic and therapeutic model based on disulfidptosis-related genes for patients with clear cell renal cell carcinoma
    Xin, Shiyong
    Su, Junjie
    Li, Ruixin
    Cao, Qiong
    Wang, Haojie
    Wei, Zhihao
    Wang, Chengliang
    Zhang, Chengdong
    Zhang, Jianguo
    Zhang, Zheng
    Li, Guanyu
    Qin, Wang
    HELIYON, 2024, 10 (11)
  • [47] Comprehensive Analysis of Disulfidptosis-Related LncRNAs in Molecular Classification, Immune Microenvironment Characterization and Prognosis of Gastric Cancer
    Kang, Kuo
    Li, Xuanxuan
    Peng, Yuanhao
    Zhou, Yangying
    BIOMEDICINES, 2023, 11 (12)
  • [48] Integrative landscape analysis of prognostic model biomarkers and immunogenomics of disulfidptosis-related genes in breast cancer based on LASSO and WGCNA analyses
    Shuyan Liu
    Yiwen Zheng
    Shujin Li
    Yaoqiang Du
    Xiaozhen Liu
    Hongchao Tang
    Xuli Meng
    Qinghui Zheng
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 16851 - 16867
  • [49] Construction of a prognostic model of colon cancer patients based on metabolism-related lncRNAs
    Li, Chenyang
    Liu, Qian
    Song, Yiran
    Wang, Wenxin
    Zhang, Xiaolan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [50] Construction and validation of prognostic model based on autophagy-related lncRNAs in gastric cancer
    Cheng, Mengqiu
    Cao, Wei
    Cao, Guodong
    Xu, Xin
    Chen, Bo
    BIOCELL, 2022, 46 (01) : 97 - 109